NCT05158647View on ClinicalTrials.gov

Adding Magnesium Sulfate to Bupivacaine for Ilioinguinal and Iliohypogastric Nerve Block

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 12, 2018

Primary Completion Date

February 7, 2020

Study Completion Date

April 21, 2020

Conditions
Magnesium Sulfate Causing Adverse Effects in Therapeutic Use
Interventions
OTHER

normal saline

10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade

DRUG

MgSo4

10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used

Trial Locations (1)

Unknown

Mahmoud S Elmansy, Al Mansurah

All Listed Sponsors
lead

Abdelrady S Ibrahim, MD

OTHER

NCT05158647 - Adding Magnesium Sulfate to Bupivacaine for Ilioinguinal and Iliohypogastric Nerve Block | Biotech Hunter | Biotech Hunter